Psychometric Properties and Correlates of Precarious Manhood Beliefs in 62 Nations

Precarious manhood beliefs portray manhood, relative to womanhood, as a social status that is hard to earn, easy to lose, and proven via public action. Here, we present cross-cultural data on a brief measure of precarious manhood beliefs (the Precarious Manhood Beliefs scale [PMB]) that covaries meaningfully with other cross-culturally validated gender ideologies and with country-level indices of gender equality and human development. Using data from university samples in 62 countries across 13 world regions (N = 33,417), we demonstrate: (1) the psychometric isomorphism of the PMB (i.e., its comparability in meaning and statistical properties across the individual and country levels); (2) the PMB’s distinctness from, and associations with, ambivalent sexism and ambivalence toward men; and (3) associations of the PMB with nation-level gender equality and human development. Findings are discussed in terms of their statistical and theoretical implications for understanding widely-held beliefs about the precariousness of the male gender role

COVID-19 vaccines and post-vaccination data: Literature update (Updated Version 10) - 02.11.2021

This report addresses the most relevant data on COVID-19 vaccines literature as of 02 November 2021. The current report addresses the latest data on vaccine effectiveness and its duration of protection, the vaccine-induced humoral, cellular, and neutralizing response over time, the effects of vaccination on transmissibility of SARS-CoV-2, vaccine booster doses, reported cases of myocarditis, the Pfizer and BioNTech vaccine in children, and the concomitant administration of the COVID-19 and Flu vaccines. To conclude, the report highlights the latest SARS-CoV-2 vaccine development information on COVID-19 vaccine candidates

COVID-19 vaccines and post-vaccination data: literature update (8) - 30.08.2021

This report addresses the most relevant data on COVID-19 vaccines literature as of 27 August, 2021. The current report addresses vaccine effectiveness against SARS-CoV-2 infection, focusing in particular, on vaccine effectiveness against variants, vaccine duration of protection, virus transmissibility and shedding post vaccination, the administration of booster doses, and the importance of children and adolescent’s timely vaccination. Lastly, the report highlights the latest updates regarding ‘new’ SARS-CoV-2 vaccines

COVID-19 vaccines in the WHO's Emergency Use Listing (EUL) Report (Updated Version 7) - 02.11.2021

This report focuses on the World Health Organization's (WHO) Emergency Use Listing (EUL) of authorized vaccines as of 02 November 2021. Currently six vaccines are authorised for emergency use: BNT162b2/COMIRNATY (Pfizer-BioNTech, USA), Spikevax/Moderna COVID-19 Vaccine/ mRNA-1273 (Moderna, USA), Vaxzevria/ChAdOx1 nCoV-19/AZD1222/Covishield (AstraZeneca/Oxford, UK, India), Janssen Covid-19 vaccine/Johnson & Johnson (Janssen, USA), Sinopharm/BBIBP-CorV (China), and Sinovac/CoronaVac (China). This report provides a condensed summary concerning vaccine efficacy, safety, protection against variants, and further important information for each vaccine, in the form of a synoptic table. The information and data in this synoptic table was extracted from phase III clinical trials and from observational studies. This report particularly focuses on the latest data on vaccine effectiveness, mRNA COVID-19 vaccine for children, duration of protection and waning immunity, and booster doses

COVID-19 vaccines and post-vaccination data: Literature update (9) - 30.09.2021

This report addresses the most relevant data on COVID-19 vaccines literature as of 27 September 2021. The current report addresses vaccine effectiveness against the Delta (B.1.617.2) variant, methodological issues in assessing vaccine effectiveness, an in-depth overview of both mRNA vaccines (Pfizer-BioNTech and Moderna), protection of booster doses against COVID-19 infections, the effects of vaccination on transmissibility of SARS-CoV-2, the characteristics of breakthrough infections, and maternal vaccinations. To conclude, the report highlights the latest SARS-CoV-2 vaccine development information on COVID-19 vaccine candidates

COVID-19 vaccines in the WHO's Emergency Use Listing (EUL) Report (10) - 15.12.2021

This report provides an in-depth review of the seven1 World Health Organization's (WHO) Emergency Use Listing (EUL) authorized vaccines: BNT162b2/ COMIRNATY (Pfizer-BioNTech, USA), Spikevax/ Moderna COVID-19 Vaccine/ mRNA-1273 (Moderna, USA), Vaxzevria/ ChAdOx1 nCoV-19/ AZD1222/ Covishield (AstraZeneca/Oxford, UK, India), Janssen Covid-19 vaccine/ Ad26CoV2.S/ Johnson & Johnson (Janssen, USA), Sinopharm/ BBIBP-CorV (China), Sinovac/ CoronaVac (China), and COVAXIN/ BBV152 (Bharat Biotech, India)]. The current report summarises the latest data on COVID-19 vaccine-related literature as of 13 December 2021, and presents the information in the form of a synoptic table. This report covers vaccine effectiveness, protection against variants, transmissibility, breakthrough infections, booster doses, COVID-19 vaccines for children, and further important information for each vaccine. The latest changes and additions to the synoptic table are highlighted in yellow

COVID-19 vaccines and post-vaccination data: Literature update (12) - 20.12.2021

Currently, the vaccination coverage in Switzerland is around 68.5% of the total population, lagging behind most of its neighbouring countries (e.g., France, Germany, and Italy). By addressing vaccine hesitancy, in addition to setting up non-pharmacological measures and interventions, many countries were more or less successful in alleviating the fifth wave of the COVID-19 pandemic. Scientists suggested that SARS-CoV-2 – the virus that causes COVID-19 – would mutate with time and that vaccination is the key element to fight such variants. Our reports are the outcome of daily COVID-19 vaccine-related literature screenings. This short report addresses the most relevant data on COVID-19 vaccines literature as of 16 December 2021. The current report addresses the latest data on the newly identified variant of concern (VOC) Omicron, vaccine duration of protection, breakthrough infections, and vaccine booster doses